S-1: Glucotrack Secures $20M Equity Line, Advances CBGM Trials

Glucotrack, Inc. has entered into a $20 million committed equity financing agreement with Sixth Borough Capital Fund, LP, while progressing its implantable continuous blood glucose monitor through human trials and addressing Nasdaq listing compliance.

Summary

• Glucotrack, Inc. (GCTK) has secured a Purchase Agreement with Sixth Borough Capital Fund, LP for up to $20.0 million in committed equity financing over a 24-month period.
• The company will issue Pre-Funded Warrants for up to 60,000 Commitment Shares to Sixth Borough as a fee for its commitment, for which Glucotrack will not receive cash proceeds.
• Glucotrack may sell up to 20,000,000 Purchase Shares to Sixth Borough at its discretion, with the purchase price based on market prices at the time of sale.
• The shares being registered for resale, including Commitment Shares, represent approximately 2,230% of the 899,410 Common Stock outstanding as of September 29, 2025, indicating significant potential dilution.
• The company has successfully completed a first-in-human acute clinical study for its implantable continuous blood glucose monitor (CBGM) in the subclavian vein, demonstrating safety and expected performance.
• A regulatory submission for a long-term first-in-human study of the fully implantable CBGM system is expected to initiate late in Q3 2025, pending approval.
• Glucotrack is preparing for pre-submission discussions with the U.S. FDA for a planned multi-center U.S. clinical trial before the end of 2025.
• The company achieved ISO 13485:2016 certification, an internationally recognized quality management standard for medical devices.
• Glucotrack has a history of net losses and negative cash flows, with an accumulated deficit of approximately $144.0 million as of June 30, 2025, and cash and cash equivalents of $9.555 million.
• The company has faced ongoing Nasdaq listing compliance issues related to minimum bid price and stockholders' equity, necessitating multiple reverse stock splits (1-for-5 in May 2024, 1-for-20 in Feb 2025, 1-for-60 in June 2025) and panel hearings.
• As of July 18, 2025, Glucotrack regained compliance with the Nasdaq Bid Price Rule, but remains under a Discretionary Panel Monitor for one year to ensure long-term compliance.
• The company's authorized shares of Common Stock were increased from 100,000,000 to 250,000,000 on January 3, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to securing significant equity financing and achieving key clinical and regulatory milestones (first-in-human study, ISO certification). However, this is tempered by substantial ongoing financial losses, a 'going concern' warning, and persistent Nasdaq listing challenges, which introduce considerable risk and uncertainty.

Positives

• Secured a $20.0 million committed equity financing facility with Sixth Borough Capital Fund, LP, providing potential capital for operations.
• Successfully completed a first-in-human acute clinical study for the Glucotrack CBGM, meeting primary safety endpoints and demonstrating expected performance.
• Achieved ISO 13485:2016 certification, a critical quality management standard recognized by major regulatory bodies like the FDA and EMA, enhancing credibility and market access.
• Demonstrated feasibility of glucose monitoring in the epidural space through 60-day preclinical studies, opening a potential new application for patients with chronic pain and diabetes.
• The Glucotrack CBGM in-vitro studies suggest a high probability of a minimum two-year implant life, with 3-year longevity feasible, which is a competitive advantage for implantable devices.
• Regained compliance with Nasdaq's Minimum Stockholders Equity Requirement and Bid Price Rule, maintaining its listing on the Nasdaq Capital Market.

Negatives

• The company has a history of significant net losses and negative cash flows from operations since inception, with an accumulated deficit of $144.0 million as of June 30, 2025.
• The independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• The potential issuance of up to 20,060,000 shares to Sixth Borough represents approximately 2,230% dilution to current shareholders based on shares outstanding as of September 29, 2025.
• The company has undergone three reverse stock splits (1-for-5, 1-for-20, 1-for-60) within a year to maintain Nasdaq listing, which can negatively impact investor perception and stock liquidity.
• Ongoing Nasdaq compliance issues, including multiple non-compliance notifications and hearings, indicate persistent challenges in meeting listing requirements.
• The company will not receive any proceeds from the resale of shares by Sixth Borough under the prospectus, only from direct sales to Sixth Borough.
• The Purchase Agreement includes limitations on the number of shares that can be sold to Sixth Borough (Exchange Cap and Beneficial Ownership Cap), which may restrict the company's ability to fully utilize the financing facility without further stockholder approval.

Risks

• Inability to predict the actual number of shares sold to Sixth Borough or the gross proceeds due to fluctuating market prices and discretion over sales timing.
• Limitations in the Purchase Agreement (e.g., Exchange Cap, Beneficial Ownership Cap) may restrict the company's ability to fully utilize the $20.0 million commitment, potentially requiring more costly capital market access.
• Dilution of existing stockholders' economic and voting interests due to the sale and issuance of a substantial percentage of Common Stock to Sixth Borough.
• Potential decrease in Common Stock price due to the sale of a large number of shares by Sixth Borough or the perception of such sales.
• Management's broad discretion over the use of proceeds from sales to Sixth Borough, which may not be invested successfully.
• No anticipated dividend payments in the foreseeable future, meaning investor returns depend solely on share price appreciation.
• Reverse stock splits may decrease the liquidity of Common Stock and may not attract new investors or improve trading liquidity.
• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows, potentially leading to curtailment of operations or liquidation of assets.
• Risk of delisting from the Nasdaq Capital Market if the company fails to maintain compliance with listing requirements, which would adversely affect liquidity, trading volume, and capital-raising ability.
• Lack of significant research coverage by securities or industry analysts could negatively impact Common Stock price.
• Provisions in charter documents and Delaware law (Section 203 DGCL) may discourage acquisitions and prevent stockholder attempts to replace management.
• Issuance of additional stock in connection with acquisitions or otherwise will dilute other stockholdings and could cause the market price to decline.

Future Outlook

Glucotrack plans to initiate a long-term first-in-human study for its fully implantable CBGM system in late Q3 2025, pending regulatory approval. The company is also preparing for pre-submission discussions with the U.S. FDA for a multi-center U.S. clinical trial expected to launch before the end of 2025. The company's ability to continue as a going concern is dependent on raising additional capital and achieving profitability.

Management Comments

• Management believes their technology, if successful, has the potential to be more accurate, more convenient, and have a longer duration than other implantable glucose monitors.
• The CEO, Paul V. Goode, is an experienced executive with a 25+ year career developing innovative medical technologies, including at Dexcom, Inc. and MiniMed.
• The CFO, Peter C. Wulff, has over 35 years of experience as a chief financial officer and chief operating officer.

Industry Context

Glucotrack operates in the rapidly evolving continuous glucose monitoring (CGM) market, which has shifted from point-in-time measurements to continuous solutions. The company's focus on an implantable CBGM for Type 1 and insulin-dependent Type 2 diabetes positions it against established players like Dexcom and Medtronic, as well as emerging implantable solutions. Its successful first-in-human study and pursuit of a long-term fully implantable device align with the industry trend towards less invasive, longer-duration, and more convenient glucose monitoring solutions. The exploration of epidural space sensing also indicates an innovative approach to address specific patient populations, potentially integrating with existing therapies.

Comparison to Industry Standards

• The Glucotrack CBGM's in-vitro feasibility study demonstrating a minimum two-year implant life, with 3-year longevity feasible, aims to surpass the typical longevity of current implantable CGM devices, such as Senseonics' Eversense, which offers 6-month and 12-month sensors.
• The first-in-human study's demonstration of similar performance and accuracy to animal studies, while not designed for accuracy evaluation, suggests a promising trajectory compared to the rigorous accuracy standards (e.g., MARD values) set by market leaders like Dexcom and Abbott's FreeStyle Libre.
• The company's executive and senior management team includes experienced professionals from industry leaders like Dexcom and Medtronic, suggesting a strong understanding of the competitive landscape and development challenges in diabetes technology.

Corporate Governance

Related Party Transactions

• On October 7, 2022, the Company acquired certain intellectual property related to the Glucotrack CBGM from Paul V. Goode, the Company's Chief Executive Officer, in exchange for cash and an obligation to issue up to 167 shares of Common Stock plus True-Up Shares based on performance milestones.
• On December 29, 2023, 17 shares of Common Stock were earned and issued to Dr. Goode on February 6, 2024.
• On May 1, 2024, 25 shares of Common Stock were earned by Dr. Goode.
• On March 26, 2025, the Board determined that the third milestone was met, and an additional 42 shares of Common Stock were earned by Dr. Goode.
• The April 22, 2024, private placement included participation from certain members of the Company's executive management and Board.
• The June 27, 2024, private placement of unsecured promissory notes and warrants included certain officers, directors, and existing investors.
• The July 18, 2024, private placement of unsecured convertible promissory notes included certain officers and directors.
• On August 23, 2024, two July 1 Investors (officers/directors) converted debt into Common Stock and warrants.
• On September 5, 2024, another July 1 Investor (officer/director) converted debt into Common Stock and warrants.
• The Concurrent Private Offering on November 14, 2024, involved the July 30 Holder, an existing investor controlled by a former director of the Company, converting debt into Common Stock and warrants.

Stakeholder Impact

• **Shareholders**: Significant dilution is expected from the potential issuance of up to 20,060,000 shares to Sixth Borough, representing approximately 2,230% of current outstanding shares. The value of existing shares may decline due to future sales by Sixth Borough. The company's ability to raise capital through this facility could provide necessary funding for operations, potentially benefiting long-term value if product development is successful.
• **Employees**: Continued R&D and clinical trial progress, supported by new financing, could provide job security and potential for growth. However, the 'going concern' warning indicates underlying financial instability that could impact employment if capital is not effectively managed or raised.
• **Customers (future)**: Progress in clinical trials and ISO certification moves the company closer to commercializing its CBGM, potentially offering a new, long-duration glucose monitoring solution for diabetes patients.
• **Creditors**: The new equity financing could improve the company's liquidity and ability to meet obligations, reducing immediate credit risk. However, the 'going concern' warning still highlights financial fragility.

Next Steps

• Initiate a long-term first-in-human study for the fully implantable Glucotrack CBGM system in late Q3 2025, pending regulatory approval.
• Prepare for pre-submission discussions with the U.S. Food and Drug Administration (FDA) for a planned multi-center U.S. clinical trial before the end of 2025.
• Utilize the $20.0 million committed equity financing from Sixth Borough Capital Fund, LP for working capital and general corporate purposes.
• Maintain compliance with Nasdaq's continued listing requirements, particularly the Bid Price Rule, under a one-year Discretionary Panel Monitor.

Key Dates

Recommendation

Glucotrack has secured a significant equity financing facility and is making tangible progress in clinical development for its implantable CBGM, including a successful first-in-human study and ISO certification. These are positive indicators for a medical device company in a high-growth market. However, the company faces substantial financial challenges, including recurring losses, a 'going concern' warning, and a history of Nasdaq listing compliance issues requiring multiple reverse stock splits. The potential for extreme dilution from the Sixth Borough transaction (over 2,200% of current shares) presents a significant risk to existing shareholders. While the long-term potential of the CBGM is promising, the immediate financial and dilution risks are high. A 'hold' recommendation is appropriate for investors who are already exposed and believe in the long-term potential, acknowledging the high risk. New investors should exercise extreme caution due to the significant dilution and financial uncertainty.

Keywords

Glucotrack, GCTK, Continuous Glucose Monitor, CBGM, Diabetes, Medical Device, SEC Filing, S-1 Registration, Equity Financing, Sixth Borough Capital, Nasdaq Listing, Reverse Stock Split, Clinical Trials, ISO 13485, FDA, Capital Raise, Warrants, Dilution